You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Treatment-Resistant Depression: When and When Not to Use Glutamate Receptor-Targeting Therapies

  • Authors: Anthony Cleare, BSc, MBBS, PhD, FRCPsych
  • CPD Released: 5/2/2022
  • Valid for credit through: 5/2/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 1.00 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of psychiatrists, primary care physicians, and neurologists practicing in Europe, the Middle East, and North Africa.

The goal of this activity is that learners will be better able to determine which patients with major depressive disorder (MDD) and treatment-resistant depression (TRD) may benefit from treatment that targets the glutamate receptor.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of N-methyl-D-aspartate (NMDA) receptor antagonists
  • Have greater competence related to
    • Selecting patients with MDD and TRD who would benefit from the use of NMDA receptor antagonists
    • Identifying when the use of NMDA receptor antagonists should be avoided in patients with MDD and TRD


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Anthony Cleare, BSc, MBBS, PhD, FRCPsych

    Professor of Psychopharmacology and Affective Disorders
    Institute of Psychiatry, Psychology and Neuroscience
    King's College London
    London, United Kingdom

    Disclosures

    Disclosure: Antony Cleare, BSc, MBBS, PhD, FRCPsych, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Janssen
    Research funding from: Protexin Probiotics International Ltd.

Editors

  • Leanne Fairley, BJ Hon

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Leanne Fairley, BJ Hon, has no relevant financial relationships.

  • Megan Breuer, PhD

    Medical Writer, WebMD Global, LLC

    Disclosures

    Disclosure: Megan Breuer, PhD, has the following relevant financial relationships: Consultant/Advisor, Paratek Pharmaceuticals, Inc. (former)

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Treatment-Resistant Depression: When and When Not to Use Glutamate Receptor-Targeting Therapies

Authors: Anthony Cleare, BSc, MBBS, PhD, FRCPsychFaculty and Disclosures

CPD Released: 5/2/2022

Valid for credit through: 5/2/2023

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

PATIENT CASE 1: PATIENT PRESENTING WITH MAJOR DEPRESSIVE DISORDER AND SEVERAL COMORBIDITIES

Arnold is a 53-year-old truck driver and has major depressive disorder (MDD). He previously received treatment with 2 antidepressants and cognitive behavioral therapy (CBT). In his current depressive episode, he received citalopram, followed by sertraline, combined with CBT. Arnold is divorced, and he can no longer support his 2 children who live with his former partner. He is struggling at work and has moved from job to job over the years. Arnold has hypertension and hypercholesterolemia, both of which are controlled with medication. He also has a history of traumatic brain injury following an accident 4 years ago, and he is recovering from an addiction to prescription painkillers. He presents with ongoing symptoms of anhedonia, fatigue, depressed mood, and lack of energy.

  • Print